Literature DB >> 2157161

Transactivation of c-fos and beta-actin genes by raf as a step in early response to transmembrane signals.

S Jamal1, E Ziff.   

Abstract

A primary response to many growth factor-induced transmembrane signals is the rapid activation of transcription of the proto-oncogene c-fos and other early-response genes, including the beta-actin gene. The c-raf gene encodes a cytoplasmic serine/threonine kinase, raf-1, whose activity is also responsive to transmembrane signals and which in mutant form can transform cells. Here we show that in transient assays, the v-raf protein, which is a constitutively activated oncogenic counterpart of raf-1, can transactivate transcription from two early-response promoters, including the c-fos promoter from human and murine cells and the human beta-actin gene promoter. Multiple elements of the human fos promoter, including the dyad symmetry element necessary for growth-factor induction, an octanucleotide direct repeat element, and the region spanning the sequence from nucleotides -225 to -99 can all serve as targets for raf induction. The c-myc promoter and two adenovirus-2 early promoters are not induced. These findings indicate that raf kinase, when activated by a transmembrane signal or by mutation of a regulatory domain, can phosphorylate a factor(s) capable of regulating transcription of the c-fos and actin genes. The oncogenic form of raf may transform by constitutively activating early response protooncogenes such as c-fos.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157161     DOI: 10.1038/344463a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  32 in total

1.  Negative autoregulation of the neu gene is mediated by a novel enhancer.

Authors:  X Y Zhao; M C Hung
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  Transcriptional activation of the CEF-4/9E3 cytokine gene by pp60v-src.

Authors:  M Dehbi; A Mbiguino; M Beauchemin; G Chatelain; P A Bédard
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

Review 3.  Fos-jun and the primary genomic response in the nervous system. Possible physiological role and pathophysiological significance.

Authors:  J P Doucet; S P Squinto; N G Bazan
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

4.  Multiple basal promoter elements determine the level of human c-fos transcription.

Authors:  L Runkel; P E Shaw; R E Herrera; R A Hipskind; A Nordheim
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

5.  Multiple interdependent regulatory sites in the mouse c-fos promoter determine basal level transcription: cell type-specific effects.

Authors:  F C Lucibello; F Ehlert; R Müller
Journal:  Nucleic Acids Res       Date:  1991-07-11       Impact factor: 16.971

6.  v-Fps-responsiveness in the Egr-1 promoter is mediated by serum response elements.

Authors:  K Alexandropoulos; S A Qureshi; M Rim; V P Sukhatme; D A Foster
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

7.  Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor.

Authors:  Paula Monje; Maria Julia Marinissen; J Silvio Gutkind
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter.

Authors:  E Flory; A Hoffmeyer; U Smola; U R Rapp; J T Bruder
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Cell transformation by c-fos requires an extended period of expression and is independent of the cell cycle.

Authors:  G G Miao; T Curran
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

Review 10.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.